William R. Hiatt, MD, is Professor of Medicine/Cardiology at the University of Colorado School of Medicine, and Chief Science Officer at CPC Clinical Research, Denver, Colorado.
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took rivaroxaban with aspirin after undergoing lower extremity revascularization had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
Data also showed that patients taking rivaroxaban had higher rates of bleeding, but there was no excess in severe bleeding events such as intracranial or fatal bleeds. Adding clopidogrel at the time of revascularization did not offer any added clinical benefit and, when added to rivaroxaban and aspirin, appeared to increase ISTH major bleeding early in treatment, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) by William R. Hiatt, MD. Dr. Hiatt is the study’s lead author.